Navigation Links
ECLINSO Announces Partnership with XClinical
Date:3/2/2012

LYNDHURST, N.J., March 2, 2012 /PRNewswire-iReach/ -- ECLINSO AG, a leading provider of clinical information technology, consulting and business process outsourcing services, announced today that it has entered into a strategic partnership agreement with XClinical GmbH. XClinical is a leading eClinical technology solutions company, offering its CDISC-certified Electronic Data Capture (EDC) and Data Management (DM) system MARVIN and related tools such as the STUDY COMPOSER and the TABULATOR.

The combined solutions, ECLINSO's trialforce Platform and XClinical's EDC system MARVIN, offer unparalleled flexibility and adaptability to both Sponsors and Clinical Research Organizations (CRO's) for capturing and managing their clinical data. Trialforce, a managed application platform, is fully compliant to the following industry standards 21 CFR 11, CDISC, HIPAA, W3C, and GCP with support for over 50 languages (including double byte languages such as Chinese). Trialforce is a cloud-based platform with no local software or hardware to support. Based on a Software as a Service (SaaS) pricing model there are minimal upfront costs, significantly lowering the initial licensing fees traditionally associated with EDC and Data Management solutions.

MARVIN can be used across all types of therapeutic areas; adapting to any type of clinical trial including Phase I-IV interventional studies, medical device trials, observational studies, registry trials, prevention studies, genetic investigations, diagnostic trials, and outcomes research. MARVIN is built on CDISC standards that enable pharmaceutical companies, CROs and MedTech companies to increase clinical trial efficiency. STUDY COMPOSER, the EDC design tool, offers an intuitive graphical point-and-click interface for defining a trial and creating relevant metadata. Study Composer automatically generates the eCRF design; the annotated CRF and data validation plan with a click of a button- all CDISC ODM compliant from the start. The solution accelerates the whole clinical trial process and thus saves time and money.

Combined with trialforce, MARVIN offers unparalleled visibility, exception management, and analysis of information from clinical trials, enabling trial sponsors and managers to make critical decisions during and throughout a trial. Integration and interoperability through other Trialforce solutions, such as IVR and ePRO, can be provided easily and seamlessly. 

"ECLINSOis extremely pleased to be able to offer MARVIN. XClinical shares our philosophy of providing innovative solutions based on industry standards, which enables interoperability within our trialforce platform. The convergence of cloud-based solutions such as Trialforce with MARVIN will significantly improve clinical trial efficiency while reducing costs."  Said Frank Pijpers, CEO of ECLINSO.

"XClinicalis delighted to have reached this partnership agreement with ECLINSO.  It enables us to offer an enterprise-level delivery and support channel for our solutions." Said Philippe Verplancke, CEO of XClinical. 

About ECLINSO (www.eclinso.com)

ECLINSO is an innovative provider of Clinical Technology solutions and global support services to enhance the conduct of clinical trials. Our international reputation combined with our deep industry understanding and innovative approach through trialforce is setting the benchmark for the use of cloud-based solutions for clinical trials. Through trialforce we deliver an innovative standards, affordable, scalable and easy-to-use platform that enables sponsors and CRO's to rapidly deploy an integrated EDC/Data Management/eClinical suite. The solution is based on an uncomplicated SaaS pricing model, that offers minimal upfront costs and significantly lower initial licensing fees compared to those fees traditionally associated with the use of EDC solutions.

ECLINSO was formed in 1995 and has offices in Basel, Switzerland, New Jersey and San Diego, USA.

About XClinical (www.xclinical.com)

XClinical GmbH, an innovative EDC-CDM system vendor based in Munich, Paris and Boston, provides solutions for the electronic management of all types of clinical trials, post-marketing studies and registries. XClinical develops and markets MARVIN, a CDISC ODM-certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM). XClinical's STUDY COMPOSER provides an intuitive graphical user interface for study setup including CRF design and data validation plan.

Media Contact: George Masoura ECLINSO, 1 855 245 0987, gm@eclinso.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ECLINSO
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Fourth-quarter 2016 revenues of $1,242 million brings ... of guidance Company reports ... associated with the write-down of goodwill and intangible assets ... Fourth-quarter reported $14.96 diluted (GAAP) ... $14.48 diluted (GAAP) loss per share from continuing operations ...
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) ... its 2017 outlook and related key planning assumptions. Executive Summary ... a 2 percent increase compared to the prior year. ... $10 million compared to net income of $15 million in ... was $24 million compared to adjusted net income of $27 ...
(Date:2/27/2017)... 27, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), ... molecular diagnostic tests and pathology services, announced today the ... upcoming United States and Canadian ... 2017 in San Antonio, Texas . ... data from the Company,s extensive experience in molecular thyroid ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 2017 , ... Much attention has been paid to the problem of men ... painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain medications ... in male populations.(1) , The proportion of women using illicit drugs is also increasing ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon ... proud to announce a new informational post on robotic hair transplantation. San Francisco ... (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):